Bristol Myers Squibb (NYSE:BMY) will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 a share.The deal represents an 88% premium to the closing price ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered ...

CAMBRIDGE, Mass., March 11, 2025--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286 million. The $5.00-per-share offer – announced ...

2seventy bio, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has successfully completed a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY). According to ...

May 07, 2025--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq ... anticipated closing of the acquisition of 2seventy by Bristol Myers Squibb (BMS) this quarter, we will continue to deliver Abecma ...

Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research and manufacturing ...

2seventy bio (NASDAQ:TSVT) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb (NYSE:BMY) in an ~$286M all-cash transaction (or $102M net of ...

2seventy bio, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has successfully completed a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY). According to InvestingPro ...

CAMBRIDGE, Mass., May 07, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for ...